OTCMKTS:CRXTQ Clarus Therapeutics (CRXTQ) Stock Price, News & Analysis → They say it’s ‘unstoppable’ – How I made 43,509% (From Investing Daily) (Ad) Free CRXTQ Stock Alerts $0.0010 0.00 (0.00%) (As of 03/6/2023) Add Compare Share Share Today's Range$0.0010▼$0.001050-Day Range N/A52-Week Range$0.00▼$3.94VolumeN/AAverage VolumeN/AMarket Capitalization$52,020.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Clarus Therapeutics alerts: Email Address Ad Investing DailyThey say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Clarus Therapeutics Stock (OTCMKTS:CRXTQ)Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.Read More CRXTQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRXTQ Stock News HeadlinesJanuary 5, 2024 | benzinga.comClarus Stock (NASDAQ:CLAR), Analyst Ratings, Price Targets, PredictionsOctober 12, 2022 | benzinga.comClarus Therapeutics Hldgs Stock (OTC:CRXWQ), Earnings Estimates, EPS, and RevenueApril 27, 2024 | Investing Daily (Ad)They say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.October 12, 2022 | benzinga.comClarus Therapeutics Hldgs Stock (OTC:CRXWQ), Analyst Ratings, Price Targets, PredictionsSeptember 5, 2022 | finance.yahoo.comClarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy CodeJuly 28, 2022 | finance.yahoo.comClarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)July 20, 2022 | wsj.comClarus Therapeutics Holdings Inc.July 12, 2022 | finance.yahoo.comClarus Therapeutics Holdings, Inc. (CRXT)April 27, 2024 | Investing Daily (Ad)They say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.June 9, 2022 | finance.yahoo.comClarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual MeetingMay 18, 2022 | seekingalpha.comClarus' oral testosterone product Jatenzo gets patent nodMay 18, 2022 | finance.yahoo.comClarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)May 16, 2022 | seekingalpha.comClarus Therapeutics Holdings, Inc. (CRXT) CEO Bob Dudley on Q1 2022 Results - Earnings Call TranscriptMay 16, 2022 | investing.comClarus Therapeutics Misses Q1 EPS by 21cMay 16, 2022 | finance.yahoo.comClarus Therapeutics Reports First Quarter 2022 Financial and Operating ResultsMay 13, 2022 | seekingalpha.comClarus Therapeutics Q1 2022 Earnings PreviewMay 12, 2022 | finance.yahoo.comClarus Therapeutics to Report First Quarter 2022 Financial and Operating ResultsMay 10, 2022 | finance.yahoo.comClarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory MastitisMay 9, 2022 | finance.yahoo.comClarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual MeetingApril 28, 2022 | finance.yahoo.comClarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)April 27, 2022 | finance.yahoo.comClarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public OfferingApril 25, 2022 | uk.investing.comWhy Clarus Therapeutics Shares Are Getting HammeredApril 25, 2022 | msn.comYou Ask, We Analyze: What To Watch For In Clarus Therapeutics Stock Following Last Week's SurgeApril 25, 2022 | seekingalpha.comClarus Therapeutics nosedives on pricing upsized $30M stock and warrants offeringApril 25, 2022 | apnews.comClarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public OfferingApril 25, 2022 | seekingalpha.comClarus Therapeutics plunges 22% on equity offeringApril 22, 2022 | nasdaq.comPre-market Movers: SCYX, DAIO, OMEX, CRSR, GPS…See More Headlines Receive CRXTQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clarus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/18/2021Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:CRXTQ CUSIPN/A CIK1817944 Webwww.clarustherapeutics.com Phone847-562-4300FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$13.96 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares52,020,000Free Float49,264,000Market Cap$52,020.00 OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Robert E. Dudley Ph.D. (Age 67)Founder, Pres, CEO & Director Comp: $800.67kMr. Richard Dale Peterson (Age 54)Chief Financial Officer Comp: $583.99kMr. Frank A. Jaeger M.A. (Age 51)M.B.A., Chief Commercial Officer Comp: $510.3kMr. Steve StarkVP of Commercial Analytics & OperationsMr. Steven A. Bourne CPA (Age 60)Chief Admin. Officer, Sec. & Treasurer Ms. Kara J. StancellVP of Investor Relations & Corp. CommunicationsMs. Rozita PassarellaVP of MarketingMr. Mike ClevelandVP of SalesDr. Jay Newmark M.B.A.M.D., Chief Medical OfficerMr. James HollowaySr. VP of Manufacturing & SupplyMore ExecutivesKey CompetitorsIgnyte AcquisitionNASDAQ:IGNYPeak BioNASDAQ:PKBODiadexusOTCMKTS:DDXSPropanc BiopharmaOTCMKTS:PPCBScopus BioPharmaNASDAQ:SCPSView All Competitors CRXTQ Stock Analysis - Frequently Asked Questions How have CRXTQ shares performed in 2024? Clarus Therapeutics' stock was trading at $0.0010 at the beginning of the year. Since then, CRXTQ shares have increased by 0.0% and is now trading at $0.0010. View the best growth stocks for 2024 here. How were Clarus Therapeutics' earnings last quarter? Clarus Therapeutics Holdings, Inc. (OTCMKTS:CRXTQ) issued its quarterly earnings results on Thursday, November, 18th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.55. The business had revenue of $4.29 million for the quarter, compared to the consensus estimate of $3.30 million. How do I buy shares of Clarus Therapeutics? Shares of CRXTQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CRXTQ) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe World's First "$20 Trillion Drug?"Behind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clarus Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
